source
- Generate Biomedicines CEO touts AI-driven shrinkage of CAR-T cell engines as huge opportunityGenerate Biomedicines' chief executive highlighted a "huge opportunity" after the company applied Anthropic's Claude AI platform to make its CAR‑T cell engines smaller. The Flagship‑founded biotec…
- Agios to cut over 202 R&D positions as it awaits FDA decision on sickle cell drugAgios Pharmaceuticals said it will eliminate more than 100 research and development positions by the end of 2026, cutting its R&D workforce by roughly 35% from 2025 levels. The company entered the…